Notice: This company has been marked as potentially delisted and may not be actively trading. Ritter Pharmaceuticals (RTTR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends RTTR vs. RAPP, PHAR, SEPN, EBS, STOK, XERS, PGEN, OMER, TRDA, and SVRAShould you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include Rapport Therapeutics (RAPP), Pharming Group (PHAR), Septerna (SEPN), Emergent BioSolutions (EBS), Stoke Therapeutics (STOK), Xeris Biopharma (XERS), Precigen (PGEN), Omeros (OMER), Entrada Therapeutics (TRDA), and Savara (SVRA). These companies are all part of the "medical" sector. Ritter Pharmaceuticals vs. Rapport Therapeutics Pharming Group Septerna Emergent BioSolutions Stoke Therapeutics Xeris Biopharma Precigen Omeros Entrada Therapeutics Savara Rapport Therapeutics (NASDAQ:RAPP) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation. Does the media prefer RAPP or RTTR? In the previous week, Rapport Therapeutics had 2 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 2 mentions for Rapport Therapeutics and 0 mentions for Ritter Pharmaceuticals. Rapport Therapeutics' average media sentiment score of 0.22 beat Ritter Pharmaceuticals' score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Rapport Therapeutics Neutral Ritter Pharmaceuticals Neutral Do insiders and institutionals hold more shares of RAPP or RTTR? 0.8% of Ritter Pharmaceuticals shares are owned by institutional investors. 15.4% of Ritter Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is RAPP or RTTR more profitable? Company Net Margins Return on Equity Return on Assets Rapport TherapeuticsN/A N/A N/A Ritter Pharmaceuticals N/A N/A -162.05% Which has preferable valuation and earnings, RAPP or RTTR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRapport TherapeuticsN/AN/A-$34.79MN/AN/ARitter PharmaceuticalsN/AN/A-$10.13MN/AN/A Does the MarketBeat Community favor RAPP or RTTR? Ritter Pharmaceuticals received 300 more outperform votes than Rapport Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Rapport Therapeutics an outperform vote while only 70.23% of users gave Ritter Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRapport TherapeuticsOutperform Votes2100.00% Underperform VotesNo VotesRitter PharmaceuticalsOutperform Votes30270.23% Underperform Votes12829.77% Do analysts rate RAPP or RTTR? Rapport Therapeutics currently has a consensus target price of $35.00, indicating a potential upside of 176.03%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Rapport Therapeutics is more favorable than Ritter Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Ritter Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryRapport Therapeutics beats Ritter Pharmaceuticals on 7 of the 11 factors compared between the two stocks. Get Ritter Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTTR vs. The Competition Export to ExcelMetricRitter PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$163.75M$7.05B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.86%P/E Ratio-5.546.1426.7919.19Price / SalesN/A268.26435.1070.89Price / CashN/A65.6738.0134.83Price / Book35.486.707.644.62Net Income-$10.13M$138.98M$3.19B$246.06M Ritter Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTTRRitter PharmaceuticalsN/A$3.55-2.0%N/A+638.6%$163.75MN/A-5.547Gap DownRAPPRapport Therapeutics1.6238 of 5 stars$16.43+1.9%$35.00+113.0%N/A$601.01MN/A0.00N/AUpcoming EarningsPHARPharming Group2.9217 of 5 stars$8.65-1.5%$27.00+212.3%-19.7%$588.12M$245.32M-33.25280Positive NewsGap UpSEPNSepterna2.2264 of 5 stars$13.17+0.6%$43.67+231.6%N/A$584.75MN/A0.00N/AAnalyst DowngradeAnalyst RevisionNews CoverageGap UpEBSEmergent BioSolutions4.2948 of 5 stars$10.10+1.0%$14.33+41.9%+185.6%$547.16M$1.05B-2.461,600STOKStoke Therapeutics3.684 of 5 stars$10.27-9.5%$21.29+107.3%+55.4%$544.00M$8.78M-4.89100Analyst ForecastAnalyst RevisionNews CoverageXERSXeris Biopharma3.725 of 5 stars$3.57+0.6%$5.15+44.3%+25.0%$532.22M$163.91M-7.93290News CoveragePositive NewsPGENPrecigen3.9293 of 5 stars$1.78+4.7%$7.00+293.3%+34.5%$521.31M$6.22M-3.24190OMEROmeros3.7781 of 5 stars$8.64-0.1%$22.50+160.4%+116.5%$500.69MN/A-3.74210Analyst ForecastNews CoverageGap UpTRDAEntrada Therapeutics3.3031 of 5 stars$12.86-0.6%$25.67+99.6%-2.0%$481.22M$129.01M8.09110Positive NewsSVRASavara2.1126 of 5 stars$2.79+0.7%$9.86+253.3%-44.0%$478.82MN/A-6.49N/APositive News Related Companies and Tools Related Companies Rapport Therapeutics Competitors Pharming Group Competitors Septerna Competitors Emergent BioSolutions Competitors Stoke Therapeutics Competitors Xeris Biopharma Competitors Precigen Competitors Omeros Competitors Entrada Therapeutics Competitors Savara Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RTTR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ritter Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
